Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

Introduction: KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Methods: In the Biomarkers France study, 4894 KRAS mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patien...

Full description

Bibliographic Details
Main Authors: Anne-Marie Ruppert, MD, PhD, Michèle Beau-Faller, MD, PhD, Didier Debieuvre, MD, L’Houcine Ouafik, MD, PhD, Virginie Westeel, MD PhD, Isabelle Rouquette, MD, Julien Mazières, MD, PhD, Pierre-Paul Bringuier, MD, Isabelle Monnet, MD, Fabienne Escande, MD, Charles Ricordel, MD, Jean-Philippe Merlio, MD, PDh, Henri Janicot, MD, Antoinette Lemoine, MD, PhD, Pascal Foucher, MD, Michel Poudenx, MD, Franck Morin, MSc, Alexandra Langlais, MSc, Pierre-Jean Souquet, MD, PhD, Fabrice Barlesi, MD, PhD, Marie Wislez, MD, PhD
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:JTO Clinical and Research Reports
Subjects:
KRAS mutation
Non–small cell lung cancer
NSCLC
Prognosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320300576

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320300576

Similar Items